Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Fresh from the Pipeline
  • Published:

Omalizumab

Nature Reviews Drug Discovery volume 3, pages 199–200 (2004)Cite this article

Abstract

Omalizumab (Xolair; Genentech/Novartis/ Tanox/Sankyo), a monoclonal antibody that binds selectively to the key allergic-reaction mediator immunoglobulin E, was approved by the FDA in June 2003 for the treatment of moderate to severe allergic asthma in patients whose symptoms are inadequately controlled by inhaled corticosteroids. Could omalizumab drive expansion of the asthma market and so reach blockbuster status?

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Mode of action of omalizumab.
Figure 2: Market for drugs to treat asthma in US $ millions.

References

  1. Lundbäck, B. Epidemiology of rhinitis and asthma. Clin. Exp. Allergy 28, S2 3–10 (1998).

    PubMed  Google Scholar 

  2. Chang, T. W. The pharmacological basis of anti-IgE therapy. Nature Biotechnol. 18, 157–162 (2000).

    Article  CAS  Google Scholar 

  3. Busse, W. W. & Lemanske, R. F. Asthma. N. Engl. J. Med. 344, 350–362 (2001).

    Article  CAS  PubMed  Google Scholar 

  4. Presta, L. G. et al. Humanization of an antibody directed against IgE. J. Immunol. 151, 2623–2632 (1993).

    CAS  PubMed  Google Scholar 

  5. MacGlashan, D. W. Jr et al. Down-regulation of FcεRI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J. Immunol. 158, 1438–1445 (1997).

    CAS  PubMed  Google Scholar 

  6. FDA Drug Approvals List [online], (cited 28 Jan 2004), <http://www.fda.gov/cder/foi/label/2003/omalgen062003LB.pdf> (2003).

  7. National Institute of Allergy and Infectious Disease. Fact Sheet #9: Asthma and its Environmental Triggers: Scientists Take a Practical New Look at a Familiar Illness [online], (cited 28 Jan 2004) <http://www.niehs.nih.gov/oc/factsheets/asthma.htm>

Download references

Author information

Authors and Affiliations

  1. Decision Resources Inc., 260 Charles Street, Waltham, 02453, Massachusetts, USA

    Stephen A. Ames & Carole D. Gleeson

  2. Nature Reviews Drug Discovery,

    Peter Kirkpatrick

Authors
  1. Stephen A. Ames
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carole D. Gleeson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter Kirkpatrick
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stephen A. Ames.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ames, S., Gleeson, C. & Kirkpatrick, P. Omalizumab. Nat Rev Drug Discov 3, 199–200 (2004). https://doi.org/10.1038/nrd1334

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd1334

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing